Related Articles
Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer
LIMITED SMALL-CELL LUNG-CARCINOMA - HIGH COMPLETE RESPONSE RATE AND SURVIVAL WITH SHORT INTENSIVE CHEMOTHERAPY AND EXTENSIVE IRRADIATION - RESULTS OF A PILOT-STUDY
Multicyclic dose-intensive chemotherapy with circulating progenitor cell support for high-risk primary breast cancer.
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: A phase II trial